Home / Market News / $LH

$LH news and market catalysts

The 30 most recent market catalysts affecting $LH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

30 catalysts 3 high impact 27 bullish 0 bearish Healthcare
Nov 18, 2026 Corporate Catalyst Bullish Impact 55
Labcorp to Expand Clinical Trial Operations in Brazil Through Collaboration with Grupo Fleury
Labcorp announced a collaboration with Grupo Fleury to expand its clinical trial operations in Brazil, establishing local kit assembly and laboratory services by late 2027. This is…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
HSBC Upgrades Labcorp to Buy From Hold
HSBC upgraded Labcorp (LH) from a 'Hold' to a 'Buy' rating, accompanied by a $40 price target. This analyst action is significant as it reflects a more optimistic view from a major…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Securities Adjusts Labcorp Price Target
Mizuho Securities has revised its price target for Labcorp Holdings Inc. (LH) upwards from $355 to $400. This change reflects Mizuho's updated and more favorable valuation outlook …
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Labcorp Holdings at Equal-Weight, Raises Price Target to $380 from $330
Barclays' decision to raise Labcorp Holdings' price target from $330 to $380, while maintaining an 'Equal-Weight' rating, signals a slightly more optimistic outlook on the company'…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
Deutsche Bank Adjusts Labcorp Price Target to $355 From $306, Maintains Hold Rating
Deutsche Bank has updated its price target for Labcorp (LH) to $355 from $306, a significant increase, after the company's third-quarter 2026 earnings report. Despite the higher pr…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Adjusts Price Target on Labcorp Holdings to $388 From $338
Morgan Stanley has raised its price target for Labcorp Holdings (LH) to $388 from $338. This adjustment comes after Labcorp's third-quarter 2026 earnings release, suggesting that t…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Price Target on Labcorp to $420 From $380, Maintains Buy Rating
UBS has updated its outlook on Labcorp, raising its price target from $380 to $420 and maintaining a 'Buy' rating. This positive revision comes after Labcorp's third-quarter 2026 e…
Oct 29, 2026 Corporate Catalyst Neutral Impact 55
Analysts Update Price Targets for Labcorp Holdings Inc.
On October 29, 2026, Truist Securities and Baird both raised their price targets for Labcorp Holdings Inc. (LH) after the company's Q3 earnings. Truist increased its target to $395…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Adjusts Price Target on Labcorp to $395 From $365
Truist Securities has revised its price target for Labcorp Holdings Inc. (LH) upwards from $365 to $395, while reiterating its 'Buy' rating. This analyst action is a direct respons…
Oct 28, 2026 Corporate Catalyst Bullish Impact 92
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp announced impressive third-quarter 2026 results, surpassing analyst expectations for both revenue and adjusted EPS. This strong performance, driven by margin expansion and …
Oct 23, 2026 Corporate Catalyst Bullish Impact 55
Labcorp Partners with Waters Corporation to Expand HPV Testing
Labcorp and Waters Corporation have formed a strategic partnership to integrate the BD Onclarity HPV Assay into Labcorp's national laboratory network, with rollout slated for late …
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Labcorp, Charles River, and FDA Announce Research Collaboration on Drug Abuse Potential
Labcorp and Charles River are partnering with the FDA to enhance scientific methods for evaluating drug abuse potential. This collaboration is significant because it aims to improv…
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Labcorp, Charles River, and FDA Partner on Drug Abuse Research
Labcorp and Charles River Laboratories have announced a research partnership with the FDA to study drug abuse potential. This collaboration is significant as it positions both comp…
Oct 15, 2026 Corporate Catalyst Bullish Impact 92
UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp is acquiring specific assets from BioReference Health, a subsidiary of OPKO Health, for a substantial $722 million in cash, plus a potential $150 million earnout. This tran…
Oct 15, 2026 Corporate Catalyst Bullish Impact 92
Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp is acquiring select assets from OPKO Health's BioReference Health subsidiary for $722 million in cash, with an additional earnout potential. This is a significant strategic…
Sep 22, 2026 Corporate Catalyst Neutral Impact 65
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029
Labcorp's 8-K filing addresses the recent release of preliminary CMS Clinical Laboratory Fee Schedule payment rates for 2027-2029. The company views these rates as potentially dama…
Sep 21, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $365
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $350 to $365. This action signals continued analyst co…
Sep 11, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $380
UBS analyst Kevin Caliendo has maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $361 to $380. This action signals continued confidence from a pro…
Sep 10, 2026 Corporate Catalyst Bullish Impact 75
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp's 8-K filing details its comprehensive growth strategy and long-term financial forecasts through 2029, including reaffirming its 2026 financial guidance. This is significan…
Sep 10, 2026 Corporate Catalyst Bullish Impact 75
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR
Labcorp's 8-K filing announces a long-term outlook through 2029, projecting a 5%-8% revenue CAGR and an 8.5%-11.5% adjusted EPS CAGR, alongside reaffirming its full-year 2026 guida…
Sep 8, 2026 Corporate Catalyst Neutral Impact 75
Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed
Labcorp (LH) has acquired MLM Medical Labs, a leading global central and specialty laboratory provider with operations in the US, Germany, and South Africa. This acquisition is sig…
Aug 31, 2026 Corporate Catalyst Bullish Impact 65
Labcorp Announces Enhancements To Digital Experience Of Labcorp Global Trial Connect, Its Portfolio Of Clinical Trial Services, Data And Technology That Enhances And Accelerates Delivery
This announcement is a moderate corporate catalyst for Labcorp (LH) as it directly enhances their core clinical trial services. The improved digital experience could lead to increa…
Aug 10, 2026 Corporate Catalyst Bullish Impact 75
Labcorp Announces FDA Approval Of PGDx elio Tissue Complete CDx As Companion Diagnostic To Identify Advanced Melanoma Patients With BRAF V600E/K Variants
The FDA approval of Labcorp's PGDx elio Tissue Complete CDx as a companion diagnostic for advanced melanoma patients with BRAF V600E/K variants is a clear positive for Labcorp, enh…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Labcorp Holdings, Raises Price Target to $360
JP Morgan's analyst Lisa Gill has reaffirmed a positive stance on Labcorp Holdings by maintaining an 'Overweight' rating and raising the price target from $330 to $360. This action…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338
Morgan Stanley's analyst Ricky Goldwasser has maintained an 'Overweight' rating on Labcorp Holdings (LH) and raised the price target from $308 to $338. This action signals continue…
Jul 31, 2026 Market Technicals Bullish Impact 55
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $320 to $350. This action signals increased confidence…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est
Labcorp Holdings (LH) filed an 8-K to announce an upward revision to its fiscal year 2026 adjusted EPS and sales guidance. The new EPS range of $18.10-$18.55 is higher than the pri…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate
Laboratory Corp (LH) announced its Q2 earnings, significantly surpassing analyst expectations for both adjusted EPS and sales. The adjusted EPS of $4.99 beat the $4.78 estimate by …
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $320
B of A Securities analyst Michael Ryskin has maintained a 'Buy' rating on Labcorp Holdings (LH) and raised the price target from $300 to $320. This action signals continued confide…
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $338
Baird analyst Eric Coldwell has maintained an 'Outperform' rating on Labcorp Holdings (LH) and raised the price target from $335 to $338. This action signals continued confidence i…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.